MapLight Therapeutics’ Schizophrenia Drug Navigates Investor Skepticism Amidst Promising Clinical Data and Broader Therapeutic Potential
admin Despite announcing positive results from a pivotal Phase 2b study for its experimental schizophrenia medicine...
biotech
FDA Advisory Committee Delivers Blow to Capricor’s Duchenne Therapy Amidst Contentious Regulatory Review and Statistical Discrepancies
In a closely watched decision that underscores the complex and often contentious landscape of rare...
Caldera, Vidya add to recent flurry of biotech mergers
The dynamic landscape of biotechnology witnessed a significant strategic shift this week as two burgeoning...
From Protocol to Patient: Inside Clinical Supply
The intricate journey of bringing scientific breakthroughs from the laboratory to patients worldwide is fraught...
Cancer Research Institute Unveils 2026 Lloyd J. Old STARs, Committing $6.25 Million to Propel High-Risk, High-Reward Immunotherapy Innovations.
The Cancer Research Institute (CRI) has officially announced the five distinguished recipients of its 2026...
Sarepta Therapeutics Appoints Michael Severino as New CEO Amidst Critical Strategic Crossroads and Post-Elevidys Challenges
Sarepta Therapeutics, a biopharmaceutical company at the forefront of genetic medicine for rare diseases, has...
FDA’s AI Ambitions Face Uncertainty Amid Leadership Departures and Shifting Strategy
The integration and evolution of artificial intelligence within the U.S. Food and Drug Administration (FDA)...
GSK Unveils Ambitious $2.5 Billion Restructuring Plan to Navigate Patent Cliff and Fuel Future Growth
London, UK – Pharmaceutical giant GSK has announced a comprehensive, multi-billion-dollar cost-cutting program designed to...
Claris Biotherapeutics Secures $118 Million Series B Funding and Fortifies Leadership for Late-Stage Eye Drug Development
Claris Biotherapeutics, a New Jersey-based biotechnology firm, has announced a significant milestone, successfully closing a...
FDA scientists question Capricor data; Legend CEO steps down
The biopharmaceutical industry experienced a dynamic week marked by significant corporate developments, regulatory challenges, and...
